Overview of computational methods employed in early-stage drug discovery

被引:7
|
作者
Skjevik, Age Aleksander [1 ]
Teigen, Knut [1 ]
Martinez, Aurora [1 ]
机构
[1] Univ Bergen, Dept Biomed, N-5009 Bergen, Norway
关键词
INTERACTION ENERGY METHOD; MOLECULAR-MECHANICS; STRUCTURAL GENOMICS; PERTURBATION METHOD; COMBINING DOCKING; SCORING FUNCTIONS; LIGAND DOCKING; BINDING; DESIGN; STATE;
D O I
10.4155/FMC.09.7
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: The understanding of biomolecular interactions ultimately depends on knowledge about the structural and dynamic details of the interacting system. Rational structure-based drug design implements computational methodology in this rationale. Discussion: Together with increasing throughput of structural biology, molecular modeling has progressively contributed to rational drug design and elucidation of nontoxic and patient-tailored interventions, helping to make drug development more cost-efficient. But in this challenging time for the pharmaceutical industry, the successful discovery of novel therapeutics should rely on integration of computational modeling with experimentation when it comes to ligand-binding energetics, system flexibility and genetic diversity/heterogeneity of the target. Moreover, it appears that many drugs even those for which specific receptors have been identified intercalate in biological membranes, which could also become the actual target. Conclusions: Understanding the drug-target and drug-unwanted-target interactions at the atomic level is fundamental in the initial phases of the drug development process. Molecular dynamics simulations and complementary computational methods are already contributing in this endeavor for the soluble pharmacological targets and show an increasing importance in the understanding of membrane-ligand interactions.
引用
收藏
页码:49 / 63
页数:15
相关论文
共 50 条
  • [1] Developing and applying computational approaches in early-stage drug discovery
    Balius, Trent
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [2] The future for early-stage tuberculosis drug discovery
    Zuniga, Edison S.
    Early, Julie
    Parish, Tanya
    FUTURE MICROBIOLOGY, 2015, 10 (02) : 217 - 229
  • [3] A critical overview of computational approaches employed for COVID-19 drug discovery
    Muratov, Eugene N.
    Amaro, Rommie
    Andrade, Carolina H.
    Brown, Nathan
    Ekins, Sean
    Fourches, Denis
    Isayev, Olexandr
    Kozakov, Dima
    Medina-Franco, Jose L.
    Merz, Kenneth M.
    Oprea, Tudor, I
    Poroikov, Vladimir
    Schneider, Gisbert
    Todd, Matthew H.
    Varnek, Alexandre
    Winkler, David A.
    Zakharov, Alexey, V
    Cherkasov, Artem
    Tropsha, Alexander
    CHEMICAL SOCIETY REVIEWS, 2021, 50 (16) : 9121 - 9151
  • [4] Exploiting genomics and proteomics for rapid, early-stage drug discovery
    Bailey, DS
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135
  • [5] Bayes optimal informer sets for early-stage drug discovery
    Yu, Peng
    Ericksen, Spencer
    Gitter, Anthony
    Newton, Michael A.
    BIOMETRICS, 2023, 79 (02) : 642 - 654
  • [6] Overview of Computational Toxicology Methods Applied in Drug and Green Chemical Discovery
    Bueso-Bordils, Jose I.
    Anton-Fos, Gerardo M.
    Martin-Algarra, Rafael
    Aleman-Lopez, Pedro A.
    JOURNAL OF XENOBIOTICS, 2024, 14 (04) : 1901 - 1918
  • [7] Theory and applications of differential scanning fluorimetry in early-stage drug discovery
    Gao K.
    Oerlemans R.
    Groves M.R.
    Biophysical Reviews, 2020, 12 (1) : 85 - 104
  • [8] Deployment of in silico and in vitro safety assays in early-stage drug discovery
    Will, Yvonne
    Schroeter, Thomas
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (10) : 1211 - 1213
  • [9] Transforming the work of early-stage drug discovery through bioprocess informatics
    Holzman, TF
    Hebert, EJ
    DRUG DISCOVERY TODAY, 2005, 10 (01) : 61 - 67
  • [10] Computational methods in drug discovery
    Leelananda, Sumudu P.
    Lindert, Steffen
    BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY, 2016, 12 : 2694 - 2718